Avior Wealth Management LLC Reduces Stock Position in Option Care Health, Inc. (NASDAQ:OPCH)

Avior Wealth Management LLC lessened its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 43.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,367 shares of the company's stock after selling 11,099 shares during the period. Avior Wealth Management LLC's holdings in Option Care Health were worth $502,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in OPCH. Wellington Management Group LLP lifted its stake in shares of Option Care Health by 84.6% in the 4th quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock valued at $425,143,000 after purchasing an additional 8,400,208 shares during the period. Norges Bank purchased a new position in Option Care Health in the fourth quarter valued at $60,219,000. Voloridge Investment Management LLC acquired a new position in shares of Option Care Health in the fourth quarter worth about $27,428,000. Freestone Grove Partners LP purchased a new stake in shares of Option Care Health during the 4th quarter worth about $17,487,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Option Care Health by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after acquiring an additional 591,042 shares during the period. Institutional investors and hedge funds own 98.05% of the company's stock.

Wall Street Analysts Forecast Growth

OPCH has been the subject of a number of analyst reports. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and upped their price target for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. JMP Securities reaffirmed a "market outperform" rating and set a $36.00 target price on shares of Option Care Health in a research note on Wednesday, June 18th. Barrington Research reiterated an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a research report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.50.

Option Care Health Price Performance

Shares of Option Care Health stock traded down $0.47 during mid-day trading on Wednesday, reaching $31.79. 1,467,267 shares of the stock traded hands, compared to its average volume of 1,882,302. The stock has a market capitalization of $5.21 billion, a PE ratio of 23.55, a PEG ratio of 1.95 and a beta of 0.74. The business has a 50-day moving average of $32.06 and a 200 day moving average of $30.70. Option Care Health, Inc. has a fifty-two week low of $21.39 and a fifty-two week high of $35.53. The company has a quick ratio of 1.02, a current ratio of 1.54 and a debt-to-equity ratio of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The firm's revenue was up 16.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 EPS. On average, analysts predict that Option Care Health, Inc. will post 1.22 EPS for the current year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.